Keyphrases
Ruxolitinib
100%
Graft-versus-host Disease (GvHD)
100%
Steroid-refractory
100%
Confidence Interval
28%
University Hospital
14%
Anemia
14%
Time Response
14%
Overall Survival
14%
Thrombocytopenia
14%
Tertiary Care
14%
Real-life Data
14%
Median Time
14%
Overall Response Rate
14%
Complete Remission
14%
Non-responders
14%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
14%
Single-center Study
14%
Dose Adjustment
14%
Severe Disease
14%
Hematologic
14%
Compassionate Use
14%
Long Follow-up
14%
Steroid Use
14%
Steroid-sparing
14%
Best Available Therapy
14%
Medicine and Dentistry
Chronic Graft Versus Host Disease
100%
Ruxolitinib
100%
Real-World Data
100%
Anemia
14%
Overall Survival
14%
Thrombocytopenia
14%
Tertiary Care
14%
Allogeneic Stem Cell Transplantation
14%
Compassionate Use
14%
Graft Versus Host Reaction
14%
Diseases
14%
Pharmacology, Toxicology and Pharmaceutical Science
Ruxolitinib
100%
Chronic Graft Versus Host Disease
100%
Remission
14%
Thrombocytopenia
14%
Overall Survival
14%
Anemia
14%
Graft Versus Host Reaction
14%
Diseases
14%